Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Torralba

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Journal of Medical Internet Research|December 8, 2025
Critical Appraisal Tools for Evaluating Artificial Intelligence in Clinical Studies: Scoping ReviewJuan B Cabello, Vicente Ruiz Garcia, Miguel Torralba, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study)Federico Pulido, Jose R Arribas, Jose M Miró, et al.
AIDS (London, England)|January 31, 2020
Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents?David Rial-Crestelo, María Antonia Sepúlveda, Francisco Javier González-Gasca, et al.
AIDS (London, England)|July 20, 2002
High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients)Jose R Arribas, Federico Pulido, Jose M Miró, et al.
European Journal of Gastroenterology & Hepatology|November 30, 2020
Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: results from a multicenter region-wide cohort study (2014-2018)David Rial-Crestelo, María Antonia Sepúlveda, Francisco Javier González-Gasca, et al.
Contact Dermatitis|June 29, 2021
Contact dermatitis from glucose sensors in Spain: A multicentric approachMaría-Elena Gatica-Ortega, Martin Mowitz, María-Antonia Pastor-Nieto, et al.
Frontiers in Cellular and Infection Microbiology|March 13, 2023
Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysisJose F Varona, Pedro Landete, Roger Paredes, et al.
Cirugia Y Cirujanos|March 29, 2022
Heridas por asta de toro, análisis de 138 casosAníbal A Medina-Velasco, Vladimir Arteaga-Peralta, Roberto De la Plaza-Llamas, et al.
Revista Espanola De Enfermedades Digestivas|December 23, 2017
Effectiveness of direct-acting antiviral therapy in patients with a HCV/HIV coinfection. A multicenter cohort studyDavid Rial-Crestelo, Miguel Rodríguez-Cola, Francisco Javier González-Gasca, et al.
Plos One|November 21, 2022
48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohortAlfonso Cabello-Ubeda, Juan Carlos López Bernardo de Quirós, Luz Martín Carbonero, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Journal of Medical Internet Research|December 8, 2025
Critical Appraisal Tools for Evaluating Artificial Intelligence in Clinical Studies: Scoping ReviewJuan B Cabello, Vicente Ruiz Garcia, Miguel Torralba, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study)Federico Pulido, Jose R Arribas, Jose M Miró, et al.
AIDS (London, England)|January 31, 2020
Does fibrosis really regress in HIV/hepatitis C virus co-infected patients after treatment with direct antiviral agents?David Rial-Crestelo, María Antonia Sepúlveda, Francisco Javier González-Gasca, et al.
AIDS (London, England)|July 20, 2002
High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients)Jose R Arribas, Federico Pulido, Jose M Miró, et al.
European Journal of Gastroenterology & Hepatology|November 30, 2020
Impact of interferon-free therapies in HIV/HCV co-infected patients on real clinical practice: results from a multicenter region-wide cohort study (2014-2018)David Rial-Crestelo, María Antonia Sepúlveda, Francisco Javier González-Gasca, et al.
Contact Dermatitis|June 29, 2021
Contact dermatitis from glucose sensors in Spain: A multicentric approachMaría-Elena Gatica-Ortega, Martin Mowitz, María-Antonia Pastor-Nieto, et al.
Frontiers in Cellular and Infection Microbiology|March 13, 2023
Plitidepsin in adult patients with COVID-19 requiring hospital admission: A long-term follow-up analysisJose F Varona, Pedro Landete, Roger Paredes, et al.
Cirugia Y Cirujanos|March 29, 2022
Heridas por asta de toro, análisis de 138 casosAníbal A Medina-Velasco, Vladimir Arteaga-Peralta, Roberto De la Plaza-Llamas, et al.
Revista Espanola De Enfermedades Digestivas|December 23, 2017
Effectiveness of direct-acting antiviral therapy in patients with a HCV/HIV coinfection. A multicenter cohort studyDavid Rial-Crestelo, Miguel Rodríguez-Cola, Francisco Javier González-Gasca, et al.
Plos One|November 21, 2022
48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohortAlfonso Cabello-Ubeda, Juan Carlos López Bernardo de Quirós, Luz Martín Carbonero, et al.
Pageof 8